RxDoctor Payments DataLook up a doctor →

David Rich, MD

Urology · Myrtle Beach, SCNPI 1790025435

Payments from drug & device makers

$13,786in general payments, 2019–2025

Across 405 payments — averaging $34.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Coloplast$3K
  • Teleflex LLC$1K
  • Boston Scientific$1K
  • Myriad Genetic Laboratories, Inc.$880
  • Pfizer$524
  • Johnson & Johnson$495
  • plus $7K from 54 others

What the payments were for

  • Consulting fees$2,00015%
  • Travel & lodging$7055%
  • Food & beverage$10,73278%
  • Education$3493%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,786 in reported general payments places this provider in the 80th percentile of 196 urology providers in South Carolina.

See all urology providers in South Carolina

Medicare billing

Part B allowed, 2024
$720,733
Medicare patients
1,852
Services billed
23,063

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OrgovyxRelugolix43$119,359
GemtesaVibegron50$44,309
MyrbetriqMirabegron36$30,007
Tamsulosin Hcl547$9,012
Finasteride333$5,890
Potassium Citrate ErPotassium Citrate52$4,546
Testosterone Cypionate131$3,451
Estradiol55$3,341
Testosterone15$2,079
Solifenacin Succinate28$976
Dutasteride29$937
Oxybutynin Chloride ErOxybutynin Chloride30$932
Alfuzosin Hcl ErAlfuzosin Hcl32$924
Methenamine Hippurate16$901
Tadalafil18$827

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Orgovyx, Gemtesa$311$163,66893 claims
Astellas Pharma US IncMyrbetriq$366$30,00736 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 196 urology providers in South Carolina.

Other urology in Myrtle Beach

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →